Today, Amgen shared its 2026 third quarter earnings report. Amgen’s employees are united by our mission to serve patients. We harness the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller, and longer.
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise,” said Robert A. Bradway, chairman and chief executive officer. “The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”
The infographic below provides more highlights about the company’s 2026 third quarter results.
Additional details can be found in the earnings press release. Please see forward-looking statements.
A webcast of the earnings call can be found on Amgen’s Investors page.
Learn More About Key Moments from Q3 at Amgen
August 31, 2026
Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke
August 27, 2026
September 8, 2026
